Taxus Companies Clash With Conor Over European Paclitaxel Patent
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific and Angiotech Pharmaceuticals are attempting to block Conor Medsystems' use of clinical trial data that would support a European CE mark for the CoStar paclitaxel-eluting stent
You may also be interested in...
Courts In Netherlands And UK Differ In Conor/Angiotech Patent Dispute
Conor Medsystems and Boston Scientific are both claiming small victories in their ongoing patent dispute related to paclitaxel-eluting stent technology after a Dutch court ruled in favor of Boston Scientific during the same week that a United Kingdom court sided with Conor
Courts In Netherlands And UK Differ In Conor/Angiotech Patent Dispute
Conor Medsystems and Boston Scientific are both claiming small victories in their ongoing patent dispute related to paclitaxel-eluting stent technology after a Dutch court ruled in favor of Boston Scientific during the same week that a United Kingdom court sided with Conor
Biosensors fends off Angiotech, Boston Scientific
Production and distribution of the Axxion drug-eluting stent continues in Europe after Biosensors prevails in a patent dispute brought by Angiotech and Boston Scientific. Biosensors' stent originally was cleared for sale in Europe in July 2005, but the firm was sued in December 2005. Angiotech and Boston Scientific claimed the device infringed a patent describing the use of paclitaxel and a polymeric coating on a stent. The news could be heartening to stent manufacturer Conor Medsystems, which is also embroiled in litigation in the Netherlands against Angiotech and Boston Scientific over the same patent (1"The Gray Sheet" Feb. 7, 2005, p. 7)...